Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
Animals
Cerebellar Neoplasms
/ genetics
Class I Phosphatidylinositol 3-Kinases
/ genetics
Disease Models, Animal
Hedgehog Proteins
/ genetics
Humans
Medulloblastoma
/ genetics
Mice, Transgenic
Mutation
Neoplasms, Experimental
/ diagnostic imaging
Patched-1 Receptor
/ genetics
Smoothened Receptor
/ genetics
Spinal Cord Neoplasms
/ secondary
Survival Rate
Whole Genome Sequencing
Medulloblastoma
Metastasis
Pik3ca mutation
Shh-pathway
Transgenic mouse model
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
20
12
2019
revised:
17
02
2020
accepted:
24
02
2020
pubmed:
1
3
2020
medline:
31
12
2020
entrez:
1
3
2020
Statut:
ppublish
Résumé
Medulloblastoma (MB) is the most frequent malignant brain tumour in children with a poor outcome. Divided into four molecular subgroups, MB of the Sonic hedgehog (SHH) subgroup accounts for approximately 25% of the cases and is driven by mutations within components of the SHH pathway, such as its receptors PTCH1 or SMO. A fraction of these cases additionally harbour PIK3CA mutations, the relevance of which is so far unknown. To unravel the role of Pik3ca mutations alone or in combination with a constitutively activated SHH signalling pathway, transgenic mice were used. These mice show mutated variants within Smo, Ptch1 or Pik3ca genes in cerebellar granule neuron precursors, which represent the cellular origin of SHH MB. Our results show that Pik3ca mutations alone are insufficient to cause developmental alterations or to initiate MB. However, they significantly accelerate the growth of Shh MB, induce tumour spread throughout the cerebrospinal fluid, and result in lower survival rates of mice with a double Pik3caH1047R/SmoM2 or Pik3caH1047R/Ptch1 mutation. Therefore, PIK3CA mutations in SHH MB may represent a therapeutic target for first and second line combination treatments.
Identifiants
pubmed: 32112900
pii: S0304-3835(20)30097-5
doi: 10.1016/j.canlet.2020.02.028
pii:
doi:
Substances chimiques
Hedgehog Proteins
0
PTCH1 protein, human
0
Patched-1 Receptor
0
SMO protein, human
0
Shh protein, mouse
0
Smoothened Receptor
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-18Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors disclose no conflicts of interest.